Intercept Pharmaceuticals (ICPT) Getting Somewhat Favorable News Coverage, Analysis Shows
Media coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.6304730379333 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Intercept Pharmaceuticals, Inc. (ICPT) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- OFL celebrates Bill 148 and will continue to Power ON for decent work (4-traders.com)
- DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) To Contact The Firm (finance.yahoo.com)
- ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017 (finance.yahoo.com)
- Zacks: Analysts Anticipate Intercept Pharmaceuticals, Inc. (ICPT) to Post -$3.39 EPS (americanbankingnews.com)
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $63.20 on Monday. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. Intercept Pharmaceuticals has a 1-year low of $54.98 and a 1-year high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter in the prior year, the firm posted ($3.59) EPS. The firm’s quarterly revenue was up 697.9% on a year-over-year basis. equities analysts predict that Intercept Pharmaceuticals will post -13.34 earnings per share for the current year.
Several equities research analysts recently issued reports on ICPT shares. Cowen Inc reiterated an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Wells Fargo & Company reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Cantor Fitzgerald restated an “underweight” rating and issued a $69.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Bank of America Corporation reduced their price objective on Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating for the company in a research note on Friday, October 13th. Finally, Robert W. Baird restated an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $144.41.
In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $117.43, for a total value of $146,787.50. Following the transaction, the chief marketing officer now directly owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,816 shares of company stock worth $297,813. Insiders own 9.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals (ICPT) Getting Somewhat Favorable News Coverage, Analysis Shows” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/intercept-pharmaceuticals-icpt-getting-somewhat-favorable-news-coverage-analysis-shows/1728166.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.